Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shicheng Su

Showing results (31-40 of 64) with videos related to

Pageof 7
Sort By:
Cancer Cell|May 31, 2024
Tumor cells impair immunological synapse formation via central nervous system-enriched metaboliteYihong Li, Min Huang, Minger Wang, et al.
Cancer Research|May 18, 2017
Tumor-Associated Macrophages Promote Malignant Progression of Breast Phyllodes Tumors by Inducing Myofibroblast DifferentiationYan Nie, Jianing Chen, Di Huang, et al.
Journal for Immunotherapy of Cancer|May 26, 2020
Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer: an open-label phase II trialJieqiong Liu, Qiang Liu, Ying Li, et al.
Cell|September 15, 2020
Targeting Mitochondria-Located circRNA SCAR Alleviates NASH via Reducing mROS OutputQiyi Zhao, Jiayu Liu, Hong Deng, et al.
Cell Metabolism|September 25, 2025
Liver-breast communication of adipocyte-oriented exosomes drives primary mammary cancer progressionChunni Li, Yiwen Lu, Yihong Li, et al.
Cell|March 7, 2020
Complement Signals Determine Opposite Effects of B Cells in Chemotherapy-Induced ImmunityYiwen Lu, Qiyi Zhao, Jian-You Liao, et al.
Nature|June 13, 2020
DNA of neutrophil extracellular traps promotes cancer metastasis via CCDC25Linbin Yang, Qiang Liu, Xiaoqian Zhang, et al.
Cancer Cell|November 15, 2022
CD16<sup>+</sup> fibroblasts foster a trastuzumab-refractory microenvironment that is reversed by VAV2 inhibitionXinwei Liu, Yiwen Lu, Jingying Huang, et al.
Medicine|December 16, 2014
Nerve fibers in breast cancer tissues indicate aggressive tumor progressionDi Huang, Shicheng Su, Xiuying Cui, et al.
Nature Communications|May 31, 2022
Multicenter phase II trial of Camrelizumab combined with Apatinib and Eribulin in heavily pretreated patients with advanced triple-negative breast cancerJieqiong Liu, Ying Wang, Zhenluan Tian, et al.
Pageof 7

Showing results (31-40 of 64) with videos related to

Sort By:
Pageof 7
Cancer Cell|May 31, 2024
Tumor cells impair immunological synapse formation via central nervous system-enriched metaboliteYihong Li, Min Huang, Minger Wang, et al.
Cancer Research|May 18, 2017
Tumor-Associated Macrophages Promote Malignant Progression of Breast Phyllodes Tumors by Inducing Myofibroblast DifferentiationYan Nie, Jianing Chen, Di Huang, et al.
Journal for Immunotherapy of Cancer|May 26, 2020
Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer: an open-label phase II trialJieqiong Liu, Qiang Liu, Ying Li, et al.
Cell|September 15, 2020
Targeting Mitochondria-Located circRNA SCAR Alleviates NASH via Reducing mROS OutputQiyi Zhao, Jiayu Liu, Hong Deng, et al.
Cell Metabolism|September 25, 2025
Liver-breast communication of adipocyte-oriented exosomes drives primary mammary cancer progressionChunni Li, Yiwen Lu, Yihong Li, et al.
Cell|March 7, 2020
Complement Signals Determine Opposite Effects of B Cells in Chemotherapy-Induced ImmunityYiwen Lu, Qiyi Zhao, Jian-You Liao, et al.
Nature|June 13, 2020
DNA of neutrophil extracellular traps promotes cancer metastasis via CCDC25Linbin Yang, Qiang Liu, Xiaoqian Zhang, et al.
Cancer Cell|November 15, 2022
CD16<sup>+</sup> fibroblasts foster a trastuzumab-refractory microenvironment that is reversed by VAV2 inhibitionXinwei Liu, Yiwen Lu, Jingying Huang, et al.
Medicine|December 16, 2014
Nerve fibers in breast cancer tissues indicate aggressive tumor progressionDi Huang, Shicheng Su, Xiuying Cui, et al.
Nature Communications|May 31, 2022
Multicenter phase II trial of Camrelizumab combined with Apatinib and Eribulin in heavily pretreated patients with advanced triple-negative breast cancerJieqiong Liu, Ying Wang, Zhenluan Tian, et al.
Pageof 7